File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jep.2011.05.035
- Scopus: eid_2-s2.0-80052035168
- PMID: 21669277
- WOS: WOS:000295236700050
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Differential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models
Title | Differential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models | ||||||
---|---|---|---|---|---|---|---|
Authors | |||||||
Keywords | Anti-metastatic Chinese medicinal formulation Colorectal cancer Matrix metalloproteinases Tian-Xian liquid Vascular endothelial growth factor | ||||||
Issue Date | 2011 | ||||||
Publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jethpharm | ||||||
Citation | Journal Of Ethnopharmacology, 2011, v. 137 n. 1, p. 403-413 How to Cite? | ||||||
Abstract | Aim of study: This study aimed to elucidate and compare the anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive components namely butanol (BU), ethyl-acetate (EA) and aqueous (WA) fractions on human colorectal cancer in vitro (HT-29 cancer cells) and in vivo (nude mouse xenografts). Materials and methods: The anti-proliferative effects of TXL and its bioactive components in HT-29 cells were determined by MTT assay. Their modulations on the potential angiogenic and metastatic marker expressions on HT-29 cells and xenografts were investigated by real-time PCR and Western blot at transcriptional and translational levels, respectively. For the in vitro study, migration abilities of HT-29 cells were determined using wound healing assay. For the in vivo study, daily measurements of the tumor size and volume of the xenografts were also performed. Results: TXL, BU, EA and WA effectively inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. The IC 50 value of TXL on HT-29 cells was obtained after incubation with 1% (v/v) TXL for 4 h; whereas IC 50 values were obtained for the following bioactive components: BU at 1.25% (v/v); EA at 5% (v/v); and WA at 0.3125% (v/v). It was found that 1% (v/v) TXL significantly down-regulated MMP2 and MMP7 expression at both transcriptional and translational levels and it reduced MMP9 and VEGF protein expression in vitro. TXL decreased the metastatic ability of HT-29 cells as demonstrated by wound healing assay. TXL and its bioactive fractions caused no significant changes in the body weight indicating lack of toxicity to the xenografts. Conclusions: In summary, TXL multi-targeted to down-regulate the metastatic markers in both in vitro and in vivo models. However, the effects of its bioactive fractions were not obvious. This study profoundly elucidated the anti-proliferative mechanism of TXL, which is vital for the development of future anti-cancer regime in Chinese medicinal formulations. © 2011 Elsevier Ireland Ltd All rights reserved. | ||||||
Persistent Identifier | http://hdl.handle.net/10722/136308 | ||||||
ISSN | 2023 Impact Factor: 4.8 2023 SCImago Journal Rankings: 0.936 | ||||||
ISI Accession Number ID |
Funding Information: The research study was supported in part by a grant from Seed Funding Programme for Applied Research (no.: 200807160015) and contract research funding from China-Japan Feida Union Company Limited. | ||||||
References | |||||||
Grants |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chu, ESM | en_HK |
dc.contributor.author | Sze, SCW | en_HK |
dc.contributor.author | Cheung, HP | en_HK |
dc.contributor.author | Wong, KL | en_HK |
dc.contributor.author | Liu, Q | en_HK |
dc.contributor.author | Ng, TB | en_HK |
dc.contributor.author | Tong, Y | en_HK |
dc.date.accessioned | 2011-07-27T02:12:56Z | - |
dc.date.available | 2011-07-27T02:12:56Z | - |
dc.date.issued | 2011 | en_HK |
dc.identifier.citation | Journal Of Ethnopharmacology, 2011, v. 137 n. 1, p. 403-413 | en_HK |
dc.identifier.issn | 0378-8741 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/136308 | - |
dc.description.abstract | Aim of study: This study aimed to elucidate and compare the anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive components namely butanol (BU), ethyl-acetate (EA) and aqueous (WA) fractions on human colorectal cancer in vitro (HT-29 cancer cells) and in vivo (nude mouse xenografts). Materials and methods: The anti-proliferative effects of TXL and its bioactive components in HT-29 cells were determined by MTT assay. Their modulations on the potential angiogenic and metastatic marker expressions on HT-29 cells and xenografts were investigated by real-time PCR and Western blot at transcriptional and translational levels, respectively. For the in vitro study, migration abilities of HT-29 cells were determined using wound healing assay. For the in vivo study, daily measurements of the tumor size and volume of the xenografts were also performed. Results: TXL, BU, EA and WA effectively inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. The IC 50 value of TXL on HT-29 cells was obtained after incubation with 1% (v/v) TXL for 4 h; whereas IC 50 values were obtained for the following bioactive components: BU at 1.25% (v/v); EA at 5% (v/v); and WA at 0.3125% (v/v). It was found that 1% (v/v) TXL significantly down-regulated MMP2 and MMP7 expression at both transcriptional and translational levels and it reduced MMP9 and VEGF protein expression in vitro. TXL decreased the metastatic ability of HT-29 cells as demonstrated by wound healing assay. TXL and its bioactive fractions caused no significant changes in the body weight indicating lack of toxicity to the xenografts. Conclusions: In summary, TXL multi-targeted to down-regulate the metastatic markers in both in vitro and in vivo models. However, the effects of its bioactive fractions were not obvious. This study profoundly elucidated the anti-proliferative mechanism of TXL, which is vital for the development of future anti-cancer regime in Chinese medicinal formulations. © 2011 Elsevier Ireland Ltd All rights reserved. | en_HK |
dc.language | eng | en_US |
dc.publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jethpharm | en_HK |
dc.relation.ispartof | Journal of Ethnopharmacology | en_HK |
dc.subject | Anti-metastatic | en_HK |
dc.subject | Chinese medicinal formulation | en_HK |
dc.subject | Colorectal cancer | en_HK |
dc.subject | Matrix metalloproteinases | en_HK |
dc.subject | Tian-Xian liquid | en_HK |
dc.subject | Vascular endothelial growth factor | en_HK |
dc.title | Differential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0378-8741&volume=137&issue=1&spage=403&epage=413&date=2011&atitle=Differential+effects+of+anti-metastatic+mechanism+of+Tian-Xian+Liquid+(TXL)+and+its+bioactive+fractions+on+human+colorectal+cancer+models | - |
dc.identifier.email | Sze, SCW: stephens@hku.hk | en_HK |
dc.identifier.email | Tong, Y: tongyao@hku.hk | en_HK |
dc.identifier.authority | Sze, SCW=rp00514 | en_HK |
dc.identifier.authority | Tong, Y=rp00509 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.jep.2011.05.035 | en_HK |
dc.identifier.pmid | 21669277 | - |
dc.identifier.scopus | eid_2-s2.0-80052035168 | en_HK |
dc.identifier.hkuros | 188145 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-80052035168&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 137 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 403 | en_HK |
dc.identifier.epage | 413 | en_HK |
dc.identifier.isi | WOS:000295236700050 | - |
dc.publisher.place | Ireland | en_HK |
dc.relation.project | Bioactive components of Tian Xian Liquid as a potential drug candidate for the treatment of colon cancer | - |
dc.identifier.scopusauthorid | Chu, ESM=13807807000 | en_HK |
dc.identifier.scopusauthorid | Sze, SCW=23482617000 | en_HK |
dc.identifier.scopusauthorid | Cheung, HP=37033470100 | en_HK |
dc.identifier.scopusauthorid | Wong, KL=47861480700 | en_HK |
dc.identifier.scopusauthorid | Liu, Q=36238108000 | en_HK |
dc.identifier.scopusauthorid | Ng, TB=35311803300 | en_HK |
dc.identifier.scopusauthorid | Tong, Y=9045384000 | en_HK |
dc.identifier.issnl | 0378-8741 | - |